Intra-Cellular aims to raise $500M; Lilly’s Prevail cuts three partnered programs

Plus, news about TScan Therapeutics, Connect BioPharma, Theolytics and Ultimovacs:

Intra-Cellular Therapies seeks $500M offering: Shortly after disclosing a Phase 3 win in depression, which could lead to an expanded label for bipolar treatment Caplyta, the biotech said it plans to raise one of the largest follow-on offerings of the year. The company’s stock $ITCI closed 23% higher on Tuesday. — Kyle LaHucik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

A Look at the Data Behind CDC’s Updated COVID Vax Decision

CDC epidemiologists conducted extensive data reviews to inform the recommendations from the Advisory Committee on Immunization Practices (ACIP) on this season’s updated monovalent COVID vaccines

September 16, 2023

‘Jarringly’ Low Hep C Cure Rates a Decade After New Treatments, CDC Says

Only one in three U.S. adults infected with hepatitis C virus (HCV) have been cured since direct-acting antivirals became available 10 years ago, CDC data

June 30, 2023

Exclusive Q&A: FDA’s principal deputy commissioner on taking over for Califf, adcomms, accelerated approvals and more

With a new presidential administration next year, FDA Principal Deputy Commissioner Namandjé Bumpus would be in line to lead the agency if current Commissioner Robert

October 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.